Combino Pharm: Zoledronic Acid Ready to Use, A New Business Opportunity
Combino Pharm presents a new business opportunity with the product Zoledronic Acid (Ready to Use...
Combino Pharm presents a new business opportunity with the product Memantine.
1. Product Description: memantine hydrochloride
2. Therapeutical indication: treatment of patients with moderate to severe Alzheimer’s disease.
3. Presentation: film-coated tablets of 10mg.
4. Highlights:
5. Patent status: European alzheimer use patent until 14/04/2014.
6. Regulatory details:
7. Regulatory Strategy: dossier completed and submission in May 2012 as a national procedure in PT.
Combino Pharm presents a new business opportunity with the product Zoledronic Acid (Ready to Use...
Combino Pharm presents a new business opportunity with the product Tobramycin for inhalation.Product description: Tobramycin...
As always, Combino Pharm will be present at the CPhI, which this year is being...
Combino Pharm's R&D facilities are based in Sant Joan Despí, Barcelona, with an R&D Center...